Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond

doi:10.3748/wjg.v29.i9.1395

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6247)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

288

WORD

HTML

4341

Figures (1-3)

429

Tables (1-6)

338

Sum=5457

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

208

Download

582

Sum=790

Mar 7, 2023 (publication date) through Jul 24, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Mar 7, 2023; 29(9): 1395-1426
Published online Mar 7, 2023. doi: 10.3748/wjg.v29.i9.1395

Table 3 Agents targeting mesenchymal epithelial transition factor receptor under clinical investigation for the treatment of colorectal cancer and metastatic colorectal cancer

Agent	Targeted molecule	Condition	Study phase	Clinical trial identifier
Savolitinib	MET	mCRC	Phase II	NCT03592641
Tivantinib	MET	mCRC	Phase I/II	NCT01075048
Onartuzumab	MET	CRC	Phase II	NCT01418222
Cabozantinib	MET/RET/VEGFR-2	CRC	Phase I	NCT02008383
		mCRC	Phase I	NCT03798626
		Refractory mCRC	Phase II	NCT03542877
Rilotumumab	HGF	KRAS wild-type mCRC	Phase I/II	NCT00788957

MET: Mesenchymal epithelial transition factor receptor; mCRC: Metastatic colorectal cancer; CRC: Colorectal cancer; VEGFR: Vascular endothelial growth factor receptor; HGF: Hepatocyte growth factor; RET: Rearranged during transfection.

Citation: Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. World J Gastroenterol 2023; 29(9): 1395-1426
URL: https://www.wjgnet.com/1007-9327/full/v29/i9/1395.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i9.1395